Search results
Results from the WOW.Com Content Network
On December 17, 2009, Rev. Bryan A. Krumm, CNP, filed a rescheduling petition for Cannabis with the DEA arguing that "because marijuana does not have the abuse potential for placement in Schedule I of the CSA, and because marijuana now has accepted medical use in 13 states, and because the DEA's own Administrative Law Judge has already ...
Yet one organizer, who helped unsuccessful petition efforts in 2022 and 2023, hopes federal reclassification of marijuana nudges more lawmakers to support legalization.
The U.S. Drug Enforcement Administration is moving toward reclassifying marijuana as a less dangerous drug. The Justice Department proposal would recognize the medical uses of cannabis, but wouldn ...
The Biden administration plans to reclassify marijuana for the first time since the Controlled Substances Act was enacted more than 50 years ago. DEA to reclassify marijuana, easing restrictions ...
The Florida Supreme Court issued a ruling on April 1 that the Florida marijuana legalization initiative, 2024 Florida Amendment 3, would appear on the November ballot. [63] On April 25, the North Dakota Secretary of State approved an adult-use legalization initiative, supported by New Economic Frontier, for signature collection.
The use, sale, and possession of cannabis over 0.3% delta-9-THC in the United States, despite state laws, is illegal under federal law.As a Schedule I drug under the federal Controlled Substances Act of 1970, cannabis over 0.3% delta-9-THC (legal term marijuana) is considered to have "no accepted medical use" and have a high potential for abuse and physical or psychological dependence.
The federal government classified cannabis as a Schedule I drug in 1970. But how much of an impact would proposed changes have on laws?
No changes are expected to the medical marijuana programs now licensed in 38 states or the legal recreational cannabis markets in 23 states, but it's unlikely they would meet the federal production, record-keeping, prescribing and other requirements for Schedule III drugs.